Key Takeaways
- Codexis (CDXS) exceeded Q4 earnings per share projections by $0.10, delivering $0.11 versus analyst expectations of $0.01
- Fourth-quarter revenue reached $38.9 million, marking an 81% increase from the prior year and surpassing the $35.83 million forecast
- The revenue boost was primarily attributed to a $37.8 million Technology Transfer Agreement executed with Merck
- Annual net loss for 2025 improved to $44.0 million compared to $65.3 million recorded in 2024
- Company projects 2026 revenue between $72 million and $76 million; current cash reserves sufficient through 2027
Codexis disclosed its fourth-quarter and complete 2025 financial performance on March 11, 2026, exceeding analyst projections for both profitability and sales figures. Shares appreciated 2.4% to reach $1.27 following the announcement.
Earnings per share for the fourth quarter registered at $0.11, outperforming the Street consensus of $0.01 by ten cents. Quarterly sales totaled $38.9 million, exceeding projections of $35.83 million and representing an 81% increase from the $21.5 million recorded in Q4 2024.
The primary catalyst behind this performance was a $37.8 million Technology Transfer Agreement finalized with Merck during the fourth quarter. This singular transaction significantly influenced the quarterly financial results.
For the complete fiscal year, overall revenue increased 19% to $70.4 million, advancing from $59.3 million in 2024. Product gross margin expanded to 64% compared to 56% in the previous year.
The annual net loss contracted to $44.0 million, equivalent to $0.50 per share, versus a $65.3 million loss, or $0.89 per share, recorded in 2024. The fourth quarter actually generated positive results — net income of $9.6 million contrasted with a $10.4 million loss during the same period last year.
Selling, general and administrative expenses decreased to $47.1 million annually, down from $55.1 million in 2024, primarily due to reduced stock-based compensation and legal expenditures. Research and development investment increased to $52.3 million from $46.3 million.
The fiscal year also incorporated $3.4 million in non-recurring restructuring expenses related to a workforce reduction implemented in November 2025.
Financial Resources and Forward Outlook
Codexis closed 2025 with $78.2 million in cash, cash equivalents and short-term investments. Management indicates this financial cushion provides operational runway through the conclusion of 2027.
For 2026, the organization forecasts total revenues ranging from $72 million to $76 million.
Regarding business development, Codexis reports active engagement with more than 40 organizations across 55 prospective opportunities. CEO Alison Moore highlighted that discussions have evolved from initial feasibility assessments toward comprehensive contractual negotiations.
The organization secured a lease for a GMP-compliant facility with kilogram-scale manufacturing capabilities. Construction modifications are anticipated to commence during the second half of 2026, with complete production capacity expected by year-end 2027.
Codexis additionally established an agreement with Axolabs — representing its third CDMO collaboration — to assess its ECO Synthesis technology at Axolabs’ production location.
Wall Street Perspective and Ownership Trends
Notwithstanding the earnings outperformance, analyst outlook remains cautious. Weiss Ratings maintained a “Sell” rating on January 21, and the MarketBeat consensus also indicates “Sell.”
Shares currently trade nearer to the 52-week low of $0.96 than the high of $3.87, with a market capitalization of $114.7 million. The 50-day moving average stands at $1.39 while the 200-day rests at $1.90.
Institutional investors have demonstrated increased interest. Millennium Management expanded its position by 3,376.5% during Q3. Renaissance Technologies increased its holdings by 137.5% in Q4. Collectively, institutional ownership represents 78.54% of outstanding shares.
The organization is pursuing a licensing arrangement with a major pharmaceutical partner during the latter half of 2026 and intends to showcase stereoisomer control data at the 2026 TIDES USA annual conference.
